India, Jan. 25 -- Biotech shares saw strong moves in Friday's after-hours session, with Sarepta leading on upcoming trial data and several peers advancing on recent clinical and regulatory updates.
Sarepta Therapeutics Inc. (SRPT) surged 9.65% to $23.17, adding $2.04 in extended trading. The move comes ahead of a highly anticipated webcast and conference call scheduled for Monday, January 26, 2026, at 8:30 a.m. Eastern Time. Sarepta will present three-year topline functional results from Part 1 of EMBARK (Study 9001-301), its global, randomized, placebo-controlled Phase 3 trial evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory children with Duchenne muscular dystrophy. Investors appear to be positioning ahead of the dat...